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Sexual disorders (both hyposexuality and sexual dysfunction) are common in people with epilepsy, occurring in up to two-
thirds of patients. However, characteristically, patients do not spontaneously report these problems. Nocturnal penile tumes-
cence testing suggests that the erectile dysfunction has a neurophysiological component. The aetiology remains uncertain
but is likely to be multifactorial, involving neurological, endocrine, iatrogenic, cognitive, psychiatric and psychosocial fac-
tors. Epilepsy-related factors include the age of onset/duration of epilepsy along with the seizure type and focus. In addi-
tion, seizure frequency might be relevant as successful epilepsy surgery can result in an improvement in sexual functioning
despite remaining on anticonvulsant medication. Endocrine changes (raised sex hormone binding globulin and reduced free
testosterone) have been reported in men with epilepsy, especially when treated with hepatic-enzyme inducing antiepileptic
drugs. Studies have not been performed evaluating anticonvulsants that do not induce hepatic enzymes such as lamotrigine.
The association between these endocrine changes and hyposexuality is not known. The relationship between seizures, hor-
mones and anticonvulsant medication in women is explored, focusing on issues such as catamenial epilepsy, the menopause,
hormone replacement therapy and the polycystic ovarian syndrome. Suggestions for future research and treatment issues are
discussed.
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INTRODUCTION
The association between epilepsy and sexual disorders
has long been known. Griesinger, in the nineteenth
century, observed ‘sexual weakness’ in the majority of
his male ‘epileptoid’ patients, as well as ‘in rare cases
long lasting morbid sexual excitement’1. Despite this,
there is still debate as to the aetiology of the dysfunc-
tion and even the extent to which epilepsy increases
the risk of sexual disorder2.
Sexual disorders associated with epilepsy can be
divided into those which are directly related to the
seizures (ictal), and those unrelated in time to seizure
occurrence (interictal).
Self-mutilation3, transvestism4, sadomasochism3,
exhibitionism3, 5 and fetishism6, have been described
in association with epilepsy, especially involving the
temporal lobes, and may be resolved with cessation of
attacks through medical or surgical treatment7. Ictal
sexual behaviour has been described (especially with
partial seizures of frontal, parietal or temporal lobe ori-
gin), particularly in women with late-onset epilepsy
and right-sided foci8. Seizures may also be provoked
by ‘normal’ sexual activity7. Hypersexuality (exces-
sive sexual activity which produces no lasting relief or
satisfaction) is also occasionally reported3. However,
the most common sexual dysfunction is the interictal
disorder of hyposexuality, which Toone7 defined as ‘a
global reduction in sexual interest, awareness and ac-
tivity’.
It is difficult to define ‘normality’ in sexual function-
ing, however information obtained from major studies
of adult sexual behaviour and sexuality may be used
as a guide. The large (2765 subject) American study
‘The Janus Report on Sexual Behavior’ revealed that
at the time of being assessed, only 1% of men and 3%
of women had never had a sexual partner and 5% of
men and 11% of women had never masturbated. Over-
all, more than 69% of men and 65% of women had
sexual activity at least weekly9.
∗An earlier version of this review was awarded the 1997 Gowers’ Prize (Young Physician Category).
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SEXUAL DYSFUNCTION IN PEOPLE WITH
EPILEPSY
Gastaut and Collomb10 were the first to undertake a
detailed but uncontrolled study of sexuality in people
with epilepsy (PWE). They described a global hypo-
sexuality in over two-thirds of their patients with tem-
poral lobe epilepsy (TLE). Since then many studies
have been performed in men with epilepsy, generat-
ing rates of sexual disorder ranging from 22%11, 12 to
67%3 (Table 1).
Toone et al.13 assessed the sexual functioning of
male patients with epilepsy attending their general
practitioners. They found that 56% of PWE had had
previous sexual intercourse, compared with 98% of
controls, with only 43% having sexual activity in the
last month, compared with 91% of controls. Also 57%
of the men with epilepsy had experienced erectile fail-
ure compared with 18% of the control group. Eighteen
percent of the patients with epilepsy, but none of the
controls, has failed to have spontaneous morning erec-
tions in the preceding year.
Fewer studies have focused on sexual dysfunction in
women (Table 1). Ndgegwa et al.14 compared sexual
satisfaction in 14 women with epilepsy and 30 con-
trols, all of whom had a regular heterosexual partner,
using the Golombok Rust Inventory of Sexual Satisfac-
tion (GRISS)15. They found that women with epilepsy
had less frequent sexual activity, more vaginismus and
generally less interest in sex. Bergen et al.16 found
34% of 50 female outpatients attending a tertiary re-
ferral centre were hyposexual according to the results
of a 20-item survey. Demerdash et al.17 assessed sex-
ual behaviour in 700 female outpatients with epilepsy.
They found psychosexual disorders in 18%, especially
with temporal lobe foci (dysfunction, 83%; paraphil-
ias, 16%; and gender identity disorders, 2%). How-
ever, they admitted that the commonest paraphilia was
‘exhibitionalism’ which constituted undressing imme-
diately after a seizure, which was most likely to be a
post-ictal automatism/confusional state rather than a
genuine paraphilia. Women with sexual disorders had
a significantly higher incidence of menstrual irregu-
larities. Interestingly, they found a high rate of sexual
prodromes (erotic arousal, 15%; sexual intercourse,
9%; and masturbation in 7%) and suggested that these
may generate negative reinforcement leading to anxi-
ety and avoidance behaviour, whenever erotic feelings
were experienced. A recent study by Stoffel-Wagner et
al.18 found that a third of women with epilepsy treated
with carbamazepine denied having any sexual interest.
Reduced fertility in people with epilepsy has also
been described; this is partly associated with lower
marriage rates but also lower fertility within mar-
riage19. Lindsay et al.20 reported the outcome of a
series of 100 children with TLE, in terms of marital
status, sexual activity and fertility. Almost all the fe-
male survivors, who were not severely handicapped,
married irrespective of age of remission. Men who
had remission of their epilepsy by the age of 12 were
more likely to marry and be sexually active. The au-
thors also found that the women produced children at
a rate three times greater than the men. Dansky et al.21
however, found that only female patients had a reduc-
tion (69%) in the expected number of live-born chil-
dren. They also found that men married less often than
women, thus the men had less children overall. Schupf
and Ottman22 compared the fertility rates in terms of
live births per person year of marriage, before and af-
ter onset of their idiopathic/cryptogenic epilepsy, with
their same-sex siblings. They found reduced fertility
rates for both sexes after but not before the onset of
their epilepsy. Risk factors for reduced fertility were
partial seizures and the development of epilepsy be-
fore the age of 10.
Other workers have not found this degree of dys-
function. Jensen et al.2 compared 86 consecutive
outpatients aged between 21 and 54 (mean 38 years)
with at least a 2-year history of epilepsy, with a control
group, using a multiple-choice ‘sexual history form’23.
The mean duration of epilepsy was 22 years, however
45% had been seizure free for the last year. They ex-
cluded patients with other medical or psychiatric dis-
orders including alcohol addiction and learning dis-
ability. Seventy-one percent of the men and 81% of
the women were married or cohabiting with a sex-
ual partner. Only 8% of men with epilepsy reported
sexual dysfunction, compared with 13% of controls.
Men with epilepsy experienced sexual desire three to
four times a week compared with once a day in the
control group. In women with epilepsy, sexual desire
was experienced twice a week compared to three to
four times a week in the control group and there was
no statistical difference in sexual dysfunction between
women with or without epilepsy. The low rates of
sexual dysfunction revealed in this study may be ex-
plained by the absence of psychosocial handicaps ex-
perienced by the PWE and their high degree of disease
acceptance2. Furthermore, two recent studies have not
shown a difference in libido and sexual functioning
between controls and either women24 or men25 with
epilepsy who were in stable relationships.
AETIOLOGY OF SEXUAL DYSFUNCTION IN
PWE
The sexual disorders associated with epilepsy do not
only include reduced desire but also an impairment of
function. There is much evidence that there may be a
neurophysiological basis to this (rather than just psy-
chogenic).
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Table 1: Sexual dysfunction in people with epilepsy.
Study Method Population N Gender % with Nature of
dysfunction dysfunction
Taylor (1969)3 I Medically 100 M: 63 86 ↓S
intractable F: 37 ED
TLE Org.Dys
Shukla et al. I TLE 44 M: 30 M: 64 ↓S
(1979)30 F: 14 F: 64
PGE 47 M: 34 M: 12
F: 13 F: 8
Walker and I Medically 50 M: 37 86 ↓S
Blumer (1975)57 intractable F: 13 ED
TLE Org.Dys
Fenwick et al. I RC with 97 M: 97 M: 64 ED
(1985)36 epilepsy Org.Dys
(mean IQ: 86)
Herzog et al. I TLE (OP) 20 M: 20 M: 55 ↓S
(1986)60 ED
Org.Dys
Toone et al. I Epilepsy 54 M: 51 57 ↓S
(1989)13 (CS) ED
Org.Dys
Jensen et al. Q OP with 86 M: 38 M: 8 ↓S
(1990)2 epilepsya F: 48 F: 29 ED
Org.Dys
Demerdash et al. I OP with 700 F: 700 F: 18 ↓S
(1991)17 epilepsy Org.Dys
Paraphilias
Murialdo et al. I OP with 37 M: 36 M: 22 ↓S
(1995)11 epilepsy ED
Husain et al. Review OP with 184 M: 184 M: 22 ↓S
(1998)12 of case epilepsy ED
notes Org.Dys
Q: questionnaire; I: interview; OP: outpatients; IP: inpatients; CS: community/ GP sample; RC: residential care; NC: normal controls;
TLE: temporal lobe epilepsy; CPS: complex partial seizures; PGE: primary generalized epilepsy; ↓S: hyposexual; ED: erectile dysfunction;
Org.Dys: orgasmic dysfunction.
a 45% were seizure free over the preceding year.
Men with epilepsy have been found to have an in-
creased risk of erectile dysfunction (ED); up to 57%13
compared with 3–9% in the general population26. This
can occur in isolation27, 28, or in conjunction with hy-
posexuality10, 29, 30. Nocturnal penile tumescence test-
ing can help differentiate whether the erectile dysfunc-
tion is of physiological or psychological origin, be-
cause if tumescence occurs during rapid eye move-
ment sleep, the ED is likely to be caused by psycholog-
ical factors. Guldner and Morrell31 assessed the fol-
lowing patients over at least two nights: six men with
TLE and ED, two with TLE and normal sexual func-
tion and one man with non-epileptic attack disorder
(NEAD) and ED. All the subjects had ‘normal sexual
desire’ (sexual thoughts, desires or behaviour at least
monthly). Five of the six patients with TLE and ED
had reduced levels of penile rigidity during nocturnal
erections but only two had reduced tumescence. Di-
minished rigidity is known to be associated with diffi-
culty in initiating and maintaining penetration and pre-
dicts the absence of spontaneous morning erections,
which reliably differentiates between organic and psy-
chogenic erectile impairment. Impaired tumescence
is associated with vasogenic ED and impaired rigid-
ity is associated with neurogenic ED32. The authors
concluded that epilepsy-related ED might have a sub-
stantial neurophysiological component31. Morrell et
al.33 compared the genital blood flow whilst watch-
ing erotic videos in eight men and nine women suf-
fering from TLE with normal controls. They found, in
both sexes, a smaller increase in genital blood flow in
the patients with epilepsy compared with the controls,
despite all subjects rating the videos as ‘moderately
arousing’. The authors concluded that sexual dysfunc-
tion in patients with epilepsy may be attributable to
physiologic disruptions in sexual arousal.
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There are many theories regarding the aetiology of
sexual dysfunction, in particular hyposexuality in peo-
ple with epilepsy, and several different factors may
play a part in an individual patient. In addition, the
weighting of each factor may vary between the sexes.
A summary of the studies investigating these associa-
tions is found in Table 2.
NEUROLOGICAL
Sexual dysfunction may be caused by a neurologi-
cal condition that is also responsible for the epilepsy,
for example cerebrovascular disorders, dementia or
brain injury, especially involving the frontal or tempo-
ral lobes34, 35. However, many of the epidemiological
studies on sexual dysfunction in PWE exclude patients
with neurological disorders other than epilepsy2, 29, 32,
thus limiting the information available about this asso-
ciation.
LEARNING DISABILITY
Fenwick et al.36 interviewed 97 adult male patients at
a centre for epilepsy, of which 80% were below the age
of 46. The mean full-scale IQ was 74 (range 34–115).
All had chronic epilepsy with a mean age of onset of
6.8 years; 75% had developed epilepsy by the age of
10 and 90% by 15 years. Most patients had partial
epilepsy (LRE), with only 9% having primary gener-
alized epilepsy (PGE). Thirty-five percent had never
experienced spontaneous penile tumescence on wak-
ing and only 21% had it most days. Forty-eight per-
cent had never experienced spontaneous tumescence
during the day and only 11% had it most days. Forty-
four percent claimed never to have had an orgasm and
64% claimed not to have had one in the last year and
only 21% of the sample admitted to having had sexual
intercourse, despite having a sexual partner. At least
one-third of those who were sexually active had dif-
ficulty in achieving and maintaining an erection. A
quarter of the patients were anxious that sexual ac-
tivity would cause a fit and 8.3% had had a seizure
during intercourse or masturbation. They found a pos-
itive relationship between having a higher IQ and hav-
ing had sexual intercourse. Many of the other studies
of sexual dysfunction in PWE have excluded patients
with learning disability2, 30, thus there is limited infor-
mation about this subject group. However, Gebhard37
assessed the sexual functioning in men with learning
disability but no epilepsy and found that 93% of the
population masturbated with an average frequency of
once a week to fortnightly and 61% had had sexual in-
tercourse. Thus, low IQ in isolation is unlikely to be a
major aetiological factor.
TYPE OF EPILEPSY
The role of the limbic system in sexuality has been
demonstrated in animal experiments and depth elec-
trode studies in man. Investigators ablated the tempo-
ral lobes in male rhesus monkeys and observed hy-
per sexuality as part of the Klu¨ver–Bucy syndrome38.
Bilateral lesions of the corticomedial amygdaloid nu-
clei in male rats severely impaired (but did not abol-
ish) sexual behaviour39 and bilateral amygdalectomy
in female monkeys produced amenorrhoea and hypog-
onadal vaginal changes40. Feeney et al.41 reported a
sudden cessation in sexual behaviour in four male cats,
1–16 weeks after focal amygdala epileptiform activ-
ity had been induced by unilateral aluminum hydrox-
ide injection. There was no change in sexual activity
in the cats with induced focal motor epilepsy. Sex-
ual function returned to baseline levels in the three
cats that remained healthy, despite ongoing tempo-
ral lobe spike activity and the presence of anticonvul-
sants. The authors suggested that compensation by the
healthy contralateral amygdala might have resulted in
the improvement in sexual functioning. Focal limbic
seizures induced by kindling of the amygdala in the
male rat produced an increase in testosterone, oestra-
diol and prolactin, whereas generalized seizures pro-
duced a transient hypogonadal state42, suggesting that
the sexual and endocrine dysfunction may be associ-
ated with temporal lobe seizure activity.
The amygdala has also been shown to have exten-
sive anatomic connections with the arcuate and pre-
optic nuclei, which are involved in the regulation of
gonadotrophin releasing hormone40. Heath43 recorded
the EEG of patients during sexual activity and found
the septal region to be the main area involved in the
orgasm, however, the amygdala, thalamic nuclei and
deep cerebellar nuclei were also involved to a lesser
extent.
Most studies, but not all16, 36 have found hypo-
sexuality to be more common in patients with focal
(LRE) seizures, especially originating from the tem-
poral lobe. Fenwick et al.36 found similar rates of sex-
ual dysfunction in patients with LRE and PGE. The
study group however was atypical (a residential centre
for patients with epilepsy) and only 9% of the sample
had PGE.
Gastaut and Collomb10 were amongst the first to
note the association between human sexual dysfunc-
tion and focal epilepsy, finding that hyposexuality was
more common in patients with seizures originating in
the rhinencephalic region.
Waxman and Geschwind44 described a ‘temporal
lobe personality’. They noted that hyposexuality oc-
curred in patients with TLE along with deepened emo-
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Table 2: Associations found in studies of patients with epilepsy and sexual dysfunction.
Study Type of Side Age of Duration Frequency of Endocrine Medication Psychiatric
epilepsy onset seizures
Blumer and — 7 — — 3 — — —
Walker (1967)29 ↓
after op→↑ ↑ if SF
Shukla et al. 3TLE — — — — — — —
(1979)30
Fenwick et al. 7 — — — 7 ↓ FT VPA: less —
(1985)36 erectile
difficulty
Herzog et al. All TLE 7 7 7 — 3↑ PRL 7 —
(1986)60 HH
HG
Toone et al. 3CPS — 3 — — 3 — —
(1989)13 ↑ TT
↑ LH
↑ LH
↑ FSH
↓ FT
Demerdash et al. 3CPS 7 — 3 — — — —
(1991)17
Bergen et al. 7 — — 7 7 — 7 —
(1992)16
Murialdo et al. 7 — 7 7 —(all were 3 7 —
(1995)11 SF) ↑ Oes
Morrel and 7 — 3 3 7 — 7 7
Guldner (1996)48
Husain et al. 7 7 7 7 7 — 7 —
(1998)12
3: association reported; 7: no association reported; –: association not investigated; ↓: decreased; ↑: increased; SF: seizure free; FT: free
testosterone; PRL: prolactin; Oes: oestradiol; HH: hypogonadotropic hypogonadism; HG: hypergonadotropic hypogonadism; VPA: valproate.
tionality, circumstantiality, hypergraphia and hyper-
religiosity.
Shukla et al.30 compared 44 adult patients with TLE
with 47 patients with PGE, by interviewing the patient
and wherever possible their spouse. They found that
over 63% of males and 64% of females with TLE
were hyposexual compared with 12% of the men and
8% of the women with generalized epilepsy. The men
with hyposexuality reported a global loss of interest in
sex, with no erections, nocturnal emissions, fantasies
or dreams of a sexual nature and had abandoned sex-
ual intercourse completely. The women only agreed to
sexual intercourse after repeated requests from their
husbands and did not experience an orgasm. Saunders
and Rawson28 also found hyposexuality to be more
common in patients with TLE.
Other researchers have found sexual dysfunction to
be more common in patients with LRE whether of
temporal or extratemporal lobe origin. Toone and his
colleagues13 compared 54 male patients with epilepsy
being treated in the community with a control group
of healthy male volunteers. The patients with epilepsy
were characterized by low levels of sexual activity and
interest as measured by a structured interview. They
found no statistical difference between the patients
with temporal lobe and non-temporal lobe epilepsy,
but found that focal epilepsy (whether temporal or
extra-temporal in origin) was associated with more
impairment than patients with PGE. Although Muri-
aldo et al.11 diagnosed sexual dysfunction in 25% of
outpatients with PGE and 20% with partial epilepsy, li-
bido was only preserved in the group with generalized
epilepsy. Fertility has also been found to be reduced
in both men and women with LRE (80% and 85%
of the expected rate, respectively), but not in patients
with PGE19.
Again, less work has focused on women. Herzog
et al.45 found that more than half of 50 women with
TLE had some menstrual disturbance. Bilo et al.46
found six out of 20 women with PGE had menstrual
problems (three of these had polycystic ovarian syn-
drome and two hypothalamic ovarian failure). Isoja¨rvi
et al.47 found a similar rate of menstrual disturbances
in women with PGE (21%), partial seizures (18%)
and secondary generalized seizures (21%). In a recent
study assessing outpatients and members of a regional
epilepsy society, women with either LRE or PGE were
found to have normal sexual desire but more than
one-third had reduced arousability. Women with LRE
reported more sexual anxiety, dyspareunia, vaginis-
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mus, arousal insufficiency and sexual dissatisfaction;
whereas women with PGE experienced anorgasmia
and sexual dissatisfaction48. Cummings et al.49 found
anovulatory cycles to be more common in women with
TLE (35.3%), compared with PGE (0%) or controls
(8.3%); however the number of patients in the study
was small.
Laterality
Several studies, but not all12, 29, 50 have demonstrated
laterality effects in patients with TLE. Herzog et al.
found diminished sexual interest in women45 and sex-
ual dysfunction in men51 with right-sided TLE. Fur-
thermore, LH pulse frequency was greater in patients
with right temporal epileptiform activity or left parox-
ysmal slowing51. Reduction of libido and frequency of
sexual intercourse has also been documented to occur
more frequently in men following a right compared
with left hemisphere stroke52. These findings have
been corroborated by a recent questionnaire study53
that revealed a reduction in sexual interest (but not per-
formance) in both men and women with right-sided
TLE, compared with patients with left-sided TLE and
normal controls.
AGE OF ONSET AND DURATION OF
EPILEPSY
Gastaut and Collomb10 observed that all the patients
with childhood-onset epilepsy developed hyposexual-
ity, compared with only two-fifths of those with on-
set after puberty. They concluded that the occurrence
of seizures prior to or during puberty might exert a
marked disturbance on the development of sexual atti-
tudes and behaviour.
Taylor3 found a trend suggesting that early-onset
epilepsy limited the chance of marriage. He also ob-
served that subjects whose epilepsy began later in life
and who were operated on later had less favourable
outcome with respect to sexuality than those with ear-
lier onset and a pathological diagnosis of mesial tem-
poral sclerosis. Lindsay et al.20 also found men who
had remission of their epilepsy by the age of 12 were
more likely to marry and be sexually active. Similarly,
Shukla et al.30 found that patients whose epilepsy had
started during childhood failed to develop any inter-
est in sexual functioning and those with late-onset
epilepsy reported a subsequent decline in both inter-
est and function.
Toone et al.13 in their community study, found
higher levels of gonadotrophins in patients with onset
of epilepsy at less than 14 years. Demerdash et al.17
also found a positive correlation between women with
sexual disorders and a longer duration of seizures.
Murialdo et al.11 however did not find a correlation
between patient age or duration of epilepsy and sex-
ual dysfunction and other authors have also found no
association12, 16, 48, thus the effect of seizures starting
before or around the time of puberty remains unclear.
FREQUENCY OF SEIZURES
Some workers have found no correlation between hy-
posexuality and seizure frequency10, 12, 36, 48. Further-
more, a recent study performed by Christianson et
al.54 failed to find differences in sexual functioning
(expect for the ability to achieve orgasm) between op-
erated and non-operated patients with epilepsy, despite
post-operative seizure control being achieved by 59%.
Toone et al.13 observed similar results in a controlled
community study to those found in an outpatient sam-
ple55, suggesting that the disturbances were unlikely
to be dependent on seizure severity or control or other
factors which may determine whether the patients
were managed by their general practitioners or hos-
pital specialists.
However, some studies appear to reveal an associa-
tion between severity of epilepsy and sexual dysfunc-
tion. Twenty-six percent of the patients in the study by
Jensen et al.2 admitted that their sexual activity had
suffered during periods of more frequent seizures and
recent studies have confirmed the reduction in libido
with increased seizure frequency24, 53. Many of the
studies documenting significant hyposexuality were in
patients seen in a tertiary referral centre or were being
assessed for epilepsy surgery3, 6 and therefore would
be expected to have more severe epilepsy. Further-
more, the studies with the lowest reports of sexual
dysfunction2, 11 were performed in patients with high
rates of seizure freedom.
Other workers, however, have found an associa-
tion between improvement in sexual functioning and
seizure control attained either with anticonvulsant
medication27, or following successful temporal lobec-
tomy6. Another study56 found improvement in non-
family relationships in 56% and in sexuality in 46% of
patients who achieved seizure freedom following tem-
poral lobectomy. No patients who continued to expe-
rience seizures had an improvement in sexuality.
Taylor3 evaluated 100 patients with TLE, pre- and
post-temporal lobectomy. He found 86 had sexual
disorders pre-operatively. Following surgery, 14 re-
mained free of sexual disorders and 22 improved and
formed successful heterosexual relationships. Sexual
functioning deteriorated post-operatively in 14 men,
but this was attributed to increasing age. Improvement
in sexuality tended to be seen most in those with great-
est seizure relief. Walker and Blumer57 followed up
50 patients, 2 to 21 years after temporal lobectomy.
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Fifty-eight percent were hyposexual before surgery.
They found that those individuals with marked or com-
plete relief of seizures had a significant improvement
in their sexuality (and in some cases the development
of hypersexuality), especially if seizures and spike dis-
charges were completely eliminated by the operation.
Those continuing to have seizures rarely showed im-
provement and may even have deteriorated. The post-
operative increase in sexuality occurred despite con-
tinued anticonvulsant medication. If seizures recurred
the hyposexuality returned.
ENDOCRINE FACTORS
Both seizures and antiepileptic drugs can affect the
hypothalamic–pituitary–gonadal axis of males and fe-
males and cause changes in hormones and sexuality.
These will be considered separately along with an ac-
count of normal functioning.
The hypothalamic–pituitary axis in men with
epilepsy
The hypothalamus controls production of the steroid
hormone testosterone by secreting gonadotrophin re-
leasing hormone (GnRH), which acts on the anterior
pituitary gland releasing follicle stimulating hormone
(FSH) and bursts of luteinizing hormone (LH). LH
stimulates the Leydig cells of the testes to produce
testosterone. Only about 2% of testosterone (T) oc-
curs as free testosterone (FT), 43–45% is bound to
sex hormone binding globulin (SHBG) and 53–55%
is bound to albumin. The testosterone bound to SHBG
is not biologically active but the testosterone that is
loosely bound to albumin may be available58. Fen-
wick and his colleagues32 found that patients with low
total and free testosterone tended to have diminished
sexual activity and reduced nocturnal penile tumes-
cence. The active testosterone is then converted to di-
hydrotestosterone (DHT) or oestradiol (E2), which can
affect sexual desire and functioning. Levels of DHT
have been positively correlated with frequency of or-
gasms in healthy men59. The hypothalamus senses the
circulating levels of DHT and E2, and responds by
regulating further production of GnRH. Testosterone
and E2 can also inhibit the pituitary release of LH.
FSH acts in the Sertoli cells of the testicles to reg-
ulate spermatogenesis. Inhibin produced by the testi-
cles regulates the production of FSH. The incidence of
hormone abnormalities seen in hyposexual men with-
out epilepsy vary depending on the clinic to which
they are referred (i.e. endocrine, psychiatric, urology),
with ranges of 4–28% having low testosterone and
0–8% high prolactin34. Hypergonadotropic hypogo-
nadism is a testicular disorder, with low testosterone
levels despite high LH input. Hypogonadotropic hy-
pogonadism can be either a primary pituitary disorder
with low LH and testosterone or a hypothalamic disor-
der with decreased GnRH release resulting in low LH
and testosterone.
Effect of epileptiform activity and seizures on
hormones in men
Herzog and his colleagues60 assessed 20 men with
TLE and found 55% to have reproductive dysfunc-
tion or hyposexuality and 45% had endocrine disor-
ders with low FT. Hypogonadotropic hypogonadism
was found in 25%, hypergonadotropic hypogonadism
in 10% and functional hyperprolactinaemia in 10%. In
a later study, they found that LH pulse frequency was
more variable in men with TLE than controls51.
It is difficult to assess the endocrine effects of
seizures alone, and thus interpret the above studies, as
most patients with active epilepsy are treated with an-
ticonvulsant medication. Spark and colleagues61, how-
ever, reported a series of 16 men with no prior diagno-
sis of epilepsy, referred for investigation of hyposexu-
ality. Eleven of this group were thought to have TLE
diagnosed clinically or by EEG and six had neuroen-
docrine abnormalities (hypogonadism with low testos-
terone in four and hyperprolactinaemia in two). Anti-
convulsant therapy restored both the hormone levels
and sexual function in two and the others improved
with additional neuroendocrine treatment. The low
testosterone may have reduced the seizure threshold
in these patients58, however, the Spark et al.61 study
has been criticized62 for using unconvincing clinical
criteria including vertigo, fainting and eneuresis for
diagnosing epilepsy. A more recent study50 suggests
that seizures per se may be responsible for the en-
docrine changes observed in PWE. Twenty-two men
with medically intractable epilepsy were compared be-
fore and after temporal lobe surgery. Serum androgen
levels (TT, FT and androstenedione) increased in half
of the 14 men who were seizure free post-operatively,
despite anticonvulsant medication being maintained.
Patients without complete seizure freedom had no sig-
nificant change in hormone levels.
Studies have shown that seizures may produce tran-
sient surges in some pituitary hormones. The hormone
prolactin (PRL) is produced by the pituitary gland
and has a large variation in baseline levels including
surges during sleep with return to daytime levels 60–
90 minutes after waking63. Serum PRL has been re-
ported to rise within 20 minutes of a spontaneous gen-
eralized seizure (GTCS) or one induced using elec-
troconvulsive therapy (ECT) with full neuromuscu-
lar relaxation (and thus no muscular activity), con-
trasting with no change following a non-epileptic at-
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tack64. Others have also found that most patients with
generalized65–68 and 39–100% with complex partial
seizures67–72 have rises in serum prolactin, compared
with only up to 10% with simple partial seizures68, 71.
The recent study by Meierkord et al.73 revealed that
complex partial seizures of frontal lobe origin were
much less likely to be associated with an elevation
of serum prolactin than seizures of temporal lobe ori-
gin, although Bauer et al.68 reported elevations in two-
thirds of patients having seizures of either frontal or
temporal lobe origin. The degree of PRL elevation
tends to be greater following GTCS69, 71, 72 and sub-
sequent seizures are followed by lower rises70. There
tends to be an ‘exhaustion’ in prolactin release dur-
ing status epilepticus74. The rise in PRL occurs within
5 minutes of the seizure onset and may remain elevated
for 1 hour post-ictally65, 66. Prolactin levels do not ap-
pear to increase following absence seizures75. Interic-
tal PRL levels tend to be normal70 but some workers
have found mildly raised levels in drug free patients61,
which may be a result of sub-clinical seizures. Hyper-
prolactinaemia has been associated with sexual dys-
function34, 76. Franks et al.77 reported impotence in
men with PRL secreting pituitary tumours and im-
provement in sexual functioning after treatment with
the dopamine agonist, bromocriptine. Studies have
also documented that the range of serum prolactin val-
ues is greater in patients with right-sided epileptiform
discharges73, 78, which may account for the increased
incidence of hyposexuality observed in some patients
with right-sided epilepsy45, 51, 53.
An increase in LH accompanying that of PRL has
been reported in men following spontaneous gener-
alized seizures71 and those induced by ECT79. In
women, both LH and FSH were elevated along with
PRL following GTCS71. Partial seizures were only as-
sociated with an increase in LH in women71.
The hypothalamic–pituitary axis in women with
epilepsy
The follicular phase begins on the first day of the
menstrual cycle, when both gonadotrophin and go-
nadal steroid levels are low. GnRH is released from
the pre-optic and mesial basal nuclei, in response to
low circulating levels of oestrogen and progesterone,
and promotes the production and secretion of FSH and
LH. This surge in release of gonadotrophins precipi-
tates ovulation. The follicle develops into the corpus
luteum, which produces progesterone and oestrogen
(luteal phase). Progesterone inhibits GnRH and con-
sequently LH. If pregnancy does not occur, atresia of
the corpus luteum results in a reduction in oestrogen
and progesterone, there is loss of the endometrium and
menstruation occurs. The cycle then repeats.
Women with epilepsy have been found to have an
increase in menstrual disorders with 25–33% of cy-
cles being reported as anovulatory18, 80, 81 compared
with 10% in women without epilepsy82. Herzog et
al.45 found that more than half a group of women
with TLE had some menstrual dysfunction including:
amenorrhoea (16%), oligomenorrhoea (20%), and an
abnormal cycle interval (20%). Two percent had hy-
perprolactinaemia, and 4% experienced a premature
menopause (compared with 1% of the normal popula-
tion). Twelve percent had hypothalamic amenorrhoea
compared with 1.5% of women without epilepsy.
Polycystic ovarian syndrome (PCO) was found in 20%
(compared with 5% in the general population) and
was associated with left-sided interictal EEG abnor-
malities. Hypogonadotropic hypogonadism was also
seen, especially with right-sided discharges. Hyposex-
uality was also associated with right-sided discharges
and low oestrogen levels. Herzog83 has reported that
these menstrual disorders are characterized by inade-
quate luteal phase cycles (low progesterone during the
second half of the menstrual cycle). Menstrual irreg-
ularities, PCO and hypothalamic ovarian failure, have
also been reported in women with PGE46. Elevation of
FSH and PRL and a blunting of LH response to GnRH
were also found in women with PGE and normal men-
strual cycles. Most of the women were taking anticon-
vulsants (phenobarbitone, valproate or a combination
of the two)46.
Herzog40 has postulated that reproductive endocrine
disorders in women may result in the development of
TLE. He suggested that the anovulatory cycles in PCO
and hypogonadotropic hypogonadism might expose
temporal lobe limbic structures to oestrogen (which is
thought to be pro-convulsant) without the normal pro-
gesterone elevation in the luteal phase, and thus pro-
mote epileptiform activity. Sharf et al.84 found that
56.5% of women with anovulatory cycles or amen-
orrhoea had EEG abnormalities, which normalized in
half with the anti-oestrogen drug, clomiphene citrate.
The effect of hormones on seizures in women
Menarche, pregnancy and the menopause can affect
seizure frequency in women. Seizures have been re-
ported as starting improving or deteriorating in fre-
quency in all three. However, in most women with
epilepsy, these times of major hormonal change have
little effect on seizure frequency83.
The relationship between changes in seizure fre-
quency and the menstrual cycle (catamenial epilepsy)
was first suggested by Locock85 and Gowers86 noted
exacerbation of seizures peri-menstrually. Since then,
catamenial exacerbation has been reported in up to
78% of women87–89, and an increase in paroxysmal
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EEG discharges has been observed in women with
epilepsy around the time of menstruation90. How-
ever, there has remained controversy as to the ex-
istence of catamenial epilepsy, with some workers
documenting a peri-menstrual exacerbation in only
12.5% of women91 and others noting a cyclical pat-
tern in men92. In a recent study93, 184 women with
intractable CPS charted their seizures and the onset of
menstruation, for one cycle, during which a mid-luteal
progesterone level was obtained. Three patterns of
catamenial epilepsy were observed. An exacerbation
either peri-menstrually or pre-ovulatory was recorded
in 71% of women with ovulatory cycles and 78% of
women with anovulatory cycles reported an increase
during the second half of the inadequate luteal phase.
Using a two-fold cyclical increase in seizures to di-
agnose catamenial epilepsy, one-third of the women
appeared to suffer form the disorder. However, it is
difficult to confidently diagnose catamenial epilepsy
on the basis of assessment over only one menstrual
cycle. Another recent study94, assessing 35 women
with TLE over an average of four cycles, revealed
that half (51.4%) of the women had exclusively ovu-
latory cycles with 23% having exclusively anovula-
tory cycles. During ovulatory cycles, the seizure fre-
quency was significantly higher during menstruation
compared with the peri-ovulatory or luteal phases.
This contrasts with the anovulatory cycles, in which
seizure frequency was lower during menstruation.
Various theories for the cause of catamenial epilepsy
have been postulated. In animal studies, oestrogen has
been found to be pro-convulsant and progesterone,
anticonvulsant95. Logothetis et al.96 observed an ex-
acerbation of paroxysmal EEG abnormalities and in
some cases clinical seizures, following IV administra-
tion of oestrogen to women with catamenial epilepsy.
The drug clomiphene acts as an antioestrogen at
the hypothalamic and pituitary levels, stimulating go-
nadotrophin secretion and ovulation, along with nor-
malization of the reproductive cycle97. Clomiphene
therapy has been shown to reduce seizure frequency in
women with partial seizures and menstrual and repro-
ductive disorders (predominantly PCO)97. Ba¨ckstro¨m
et al.98 observed a reduction in interictal spike fre-
quency in women with partial seizures when a pro-
gesterone infusion produced luteal-phase blood lev-
els. Catamenial seizures in ovulatory cycles may be
the result of an increase in oestrogen around ovulation
or the marked and rapid pre-menstrual decline in pro-
gesterone levels, which tends to be more pronounced
in ovulatory cycles. Anovulatory cycles are charac-
terized by an inadequate luteal phase (diagnosed by
the absence of the usual 10-day increase in body
temperature and by a low mid-luteal progesterone
level). The resultant raised oestradiol/progesterone ra-
tio may precipitate seizures40. The luteal phase in-
crease in progesterone may thus be protective against
seizures and the absence of this during anovulatory
seizures may result in a generally higher seizure fre-
quency not necessarily menstrually related94. These
hormonal effects are thought to be mediated via
the GABAA and NMDA receptors99. Other expla-
nations for these cyclical seizures have been sug-
gested. A fall in phenytoin (PHT) levels has been doc-
umented peri-menstrually in women with catamenial
epilepsy88, 100, 101. However, Ba¨ckstro¨m and Jorpes102
did not find any change in PHT, phenobarbitone (PB)
or carbamazepine (CBZ) levels throughout the men-
strual cycle. Pre-menstrual tension (PMT) has also
been suggested as an aetiological factor. Rosciszewska
et al.88 commented that more women with catame-
nial epilepsy suffered form pre-menstrual tension and
therefore changes in electrolyte and water balance may
play a role in the seizure exacerbation, and Craw-
ford103 commented that stress and anxiety, which are
features of PMT, are recognized seizure precipitants.
Progesterone therapy has been used as a treat-
ment for uncontrolled catamenial seizures. Cyclic nat-
ural progesterone produced a decline in seizure fre-
quency in almost three-quarters of women with cata-
menial epilepsy104. Synthetic progestogen has also
been found to be efficacious105–107, the best response
occurring with the depot preparation of medroxypro-
gesterone acetate. However, caution should be exer-
cised in administering progesterone to women with
generalized seizures, as absence seizures may be exac-
erbated108, 109. Recently, it has been shown in a small,
uncontrolled study110, that seizure control improved
when the synthetic gonadotrophin releasing hormone
(GnRH) agonist triptorelin (which has a long-term
inhibitory effect on gonadotrophin release and sup-
presses the menstrual hormonal rhythm) was given
to women with catamenial epilepsy. Other treatment
approaches include the peri-menstrual addition of a
benzodiazepine such as clobazam to the treatment
regime111, or the use of the anticonvulsant acetazo-
lamide, which is a carbonic anhydrase inhibitor and
has mild diuretic properties112.
Little attention has been paid to the effect of the
menopause or hormone replacement therapy (HRT) in
women with epilepsy. However, there have been two
recent studies addressing this area113, 114. The peri-
menopause is defined as the onset of irregular men-
struation accompanied by hot flushes and mood distur-
bances. During this time the oestrogen : progesterone
ratio becomes higher. Harden et al.114 found that 23%
of 39 peri-menopausal women experienced no change
in seizure frequency at this time, with 13% experi-
encing a decrease and 64% an increase. A history of
catamenial epilepsy was associated with an increase
in seizures. The menopause is defined as the absence
of menstruation for at least 1 year, and is accom-
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panied by a marked reduction in oestrogen produc-
tion. Menopausal exacerbation of seizures has been re-
ported in 31% of women, and improvement in 41%114.
Harden et al.114 also showed that 68% of patients with
a history of catamenial seizures reported a menopausal
decrease in seizure frequency. Abassi et al.113 found
that 20% of 61 menopausal women related the on-
set of their seizures to the menopause. However, both
these studies were retrospective and further large-scale
prospective studies are needed. Very little is known
about the effect of HRT in post-menopausal women
with epilepsy. There is obvious concern about giv-
ing a potentially proconvulsant drug (oestrogen) to a
patient with epilepsy. However, the dramatic decline
in natural oestrogen, caused by the involution of ovar-
ian follicles during the menopause, should render the
risk minimal. In the study by Abbasi et al.113 three
women had been advised against taking HRT by their
physicians because of fear of exacerbating seizures. Of
the 31 women who had taken HRT, 71% reported no
change in seizure frequency, 16% some improvement
and 13% worsening. None of the women who were
known to be taking progestogen along with the oestro-
gen suffered a worsening of their seizures and in fact
half noted a decrease in seizure frequency. However,
Harden et al.114 found 63% of women receiving HRT
(usually combined oestrogen and progestogen) suf-
fered an exacerbation of seizures. Further prospective
studies need to be performed in this area, especially
in light of the concern that AEDs are associated with
bone disorders (osteomalacia, osteoporosis)115–124
which may result in bone fractures125, which are also
more common in post-menopausal women.
ANTICONVULSANT MEDICATION
The relationship between anticonvulsants and hypo-
sexuality has long been known. Bromides were first in-
troduced to treat the hypersexuality that was believed
to be associated with epilepsy85. However, the actual
role that antiepileptic drugs (AEDs) play in the devel-
opment of sexual dysfunction remains a controversial
issue. This review will attempt to address this.
Studies implicating AEDs
Studies conducted in subjects not suffering from
epilepsy
A normal volunteer study suggests that AEDs per se
may have an effect on reproductive hormones. Con-
nell et al.126 gave CBZ to subjects without epilepsy
and found a rise in SHBG, along with a fall in TT, FT
and DHT within 7 days of starting the medication. The
hormone levels normalized however, within 3 weeks
of continued therapy.
Ejaculatory failure (unaccompanied by ED or a re-
duction in libido) has also been reported in a man tak-
ing CBZ for trigeminal neuralgia127 and in another
taking gabapentin for hypomania128. In both cases or-
gasm and ejaculation returned to normal after with-
drawing the AED, suggesting that medication even in
the absence of a seizure history may be associated with
sexual dysfunction.
Studies evaluating AEDs in PWE
Christiansen and Lund129 evaluated the effects of
AEDs on male hormones and sexual functioning. They
found lowered levels of androgens and raised oestro-
gen, which correlated with reduced potency. Sper-
matogenesis was also impaired, half the patients had
low semen volume, 57% low sperm count, 89% ab-
normal sperm morphology, 96% low motility and 96%
impaired fertility. Since then, few studies have per-
formed semen analysis. However, low volume of sem-
inal fluid has been associated with PHT130 and val-
proate (VPA)131; low spermatozoa concentration and
count with PHT130 and VPA131; and inhibited sperm
motility (both in vitro and in vivo studies) with PHT,
CBZ and VPA132. However, Taneja et al.130 also re-
ported a low volume of seminal fluid, reduced sper-
matozoa concentration and count in untreated men
with epilepsy.
Many other workers have also found hormonal ab-
normalities in patients taking AEDs (Table 3). Bar-
ragry et al.133 found elevated TT and SHBG in men
with epilepsy treated with the liver-enzyme induc-
ing AEDs: PB, PHT and CBZ. Toone and his col-
leagues134, reported increases in TT, DHT, LH, FSH,
SHBG and PRL, along with a decrease in FT in men
with epilepsy taking AEDs. Low sexual drive has been
found to be associated with a reduction in FT134 and
raised LH13. Lower PRL and higher TT and SHBG
were reported in patients on polytherapy55. These find-
ings have been observed in residential centres36, hos-
pital outpatients135 and community studies13.
Most studies have assessed patients on AED poly-
therapy. Macphee et al.136 assessed circulating hor-
mones in 41 men with epilepsy on monotherapy (18
taking CBZ, 13 PHT and 10 VPA) and compared them
with 12 patients on polytherapy (POLY) and 40 con-
trols, of which 14 were untreated PWE. None of the
patients were thought to have had a seizure within the
previous 48 hours, although EEG monitoring had not
been performed therefore subclinical seizure activity
may have occurred. They did not find any significant
differences between untreated PWE and the controls
without epilepsy, suggesting that epilepsy per se did
not affect the hormone profile. Raised SHBG levels
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Table 3: Hormone changes reported in men with epilepsy.
Untreated PB/Prim PHT CBZ VPA POLY
SHBG ↔ 25,136, ↑ 11,133 ↑ 11,25,133, ↑ 11,18,25, ↔ 25,136, ↑ 25,55,133,
138,141,143 136,138,141, 133,138,141, 138,141,143 134,136
143 143
TT ↔ 25,136, ↔ 11 ↔ 11 ↔ 11,18,138, ↔ 25,136 ↑ 25,55,133,
138,141,143 ↑ 133 ↑ 25,133,138, 141,143 134
141,143 ↑ 133
FT ↔ 25,136, ↓ 11 ↓ 11 ↓ 11,18,136 ↔ 25,136 ↓ 55,134,136
138,141,143 ↔ 25 ↔ 25,138, ↔ 25
141,143
FAI ↔ 25,138, — ↓ 25,138,141, ↓ 25,138,141, ↔ 25,138, ↓ 25
141,143 143 143 141,143
DHAS ↔ 25,136, — ↓ 25,136,138, ↓ 18,25,136, ↔ 25,136, ↓ 25,136
138,141,143 141,143 138,141,143 138,141,143
E2 ↑ 138,141,143 ↑ 11 ↑ 11,145 ↔ 18,25,138, ↔ 25 ↔ 25
↔ 25 ↔ 25 141,143
↑ 11
FSH ↔ 136, — — ↔ 138,141,143 ↔ 136 ↑ 55,134
138,141,143 ↑ 18
LH ↔ 136, — ↑ 136 ↑ 18,136 ↔ 136 ↑ 55,134,136
138,141,143 ↔ 138,141,143
SHBG: sex hormone binding globulin; TT: total testosterone; FT: free testosterone; FAI: free androgen index; E2: oestrogen; FSH: follicle
stimulating hormone; LH: luteinizing hormone; ↑: increased; ↓: decreased;↔: as controls.
Sources: Barragry et al.133; Toone et al.55, 134; Macphee et al.136; Isoja¨rvi et al.138, 143; Herzog et al.145; Murialdo et al.11; Stoffel-Wagner
et al.18; Duncan et al.25
were found in patients taking PHT monotherapy and
the POLY group. Free testosterone was reduced ac-
companied by an increase in LH in the CBZ and POLY
group. Basal PRL was raised only in the group on CBZ
monotherapy. VPA did not appear to affect the level of
any measured hormone and the authors suggested that
VPA may be a useful AED for male patients reporting
sexual dysfunction.
Further support that AEDs effect pituitary respon-
siveness was provided by Isoja¨rvi et al.137, who
found lower basal serum LH concentrations in women
treated with CBZ and lower basal PRL with a higher
response to thyrotropin-releasing hormone (TRH) in
male patients treated with CBZ compared with un-
medicated PWE.
Dehydroepiandrosterone (DHAS) is an androgen
synthesized by the adrenal gland and is not directly
under pituitary control. It has been found to be re-
duced early in the course of CBZ treatment, in both
men138 and women139. Macphee et al.136 also found
a marked reduction in DHAS in all groups of patients
taking enzyme inducing AEDs (PHT and CBZ), but
not in those taking VPA alone. SHBG has been shown
to be elevated by treatment with liver-enzyme induc-
ing drugs (primidone, PB, PHT and CBZ), but not
VPA or diazepam140, 141. However, Lu¨hdorf et al.142
observed elevated TT in untreated patients on com-
mencing VPA.
Isoja¨rvi et al.141 assessed the free-androgen in-
dex (FAI), which is a measure of non-SHBG-bound
testosterone, and found it to be decreased despite nor-
mal FT. In a later study, it was found that men who had
been taking CBZ and PHT for more than 5 years had
raised SHBG and lowered FAI. They prospectively
assessed patients beginning CBZ therapy and found
testosterone levels remained the same, but SHBG lev-
els increased progressively accompanied by a reduc-
tion in FAI, starting in the first year of treatment. They
also noted that patients who had been on these drugs
for more than 20 years developed sexual dysfunction
despite normal libido143. Since the levels of SHBG in-
creased progressively over time, this may explain the
findings of some workers that sexual dysfunction is
more common in men with early age of starting treat-
ment.
Murialdo et al.11 studied LH pulsatile secretion, go-
nadotrophin and PRL responses to LHRH in 37 male
outpatients with epilepsy, receiving AED monother-
apy (PB, PHT or CBZ) who were seizure free. Total
testosterone levels were normal, but lower levels of
FT and DHT, and higher levels of SHBG were found
compared with a control group without epilepsy. There
were no significant differences between patients with
normal or reduced sexuality, however patients with
sexual dysfunction were found to have decreased LH
response to LHRH which would be consistent with
subclinical hypogonadotropic hypogonadism. Higher
oestradiol was also found and the FT/E2 values were
<1 in hyposexual patients and>1 in men with normal
sexual function.
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Many of the studies assessing endocrine status in
PWE have not examined sexual desire and func-
tion in the same patients. However, there have been
some recent exceptions. Duncan et al.25 compared
118 treated men with epilepsy, with untreated and
normal controls, using the Frenken Sexuality Expe-
rience Scales (SES)144. They found raised SHBG in
patients taking CBZ, PHT and polytherapy. DHAS
was lower in patients taking CBZ and PHT monother-
apy. They did not find any significant differences in
FT and E2 levels between the study groups, although
the mean levels of E2 in the men taking CBZ or PHT
monotherapy were higher than in the controls. In ad-
dition, FAI was lower in the CBZ, PHT and poly-
therapy groups. Untreated patients and those taking
VPA did not appear to have significantly different hor-
mone levels than the control group. They found that
the men taking AEDs had a stricter sexual morality
than controls and were more satisfied with their mar-
riages. They did not find any difference in libido and
sexual function between the groups25. However, the
SES is composed of four sections and only patients
in a stable relationship can complete the parts of the
questionnaire covering sexual desire and function (in-
cluding morning erections). Men with reduced libido
and/or sexual dysfunction may not have entered into
relationships and therefore would have been missed.
Stoffel-Wagner et al.18 assessed sexuality by inter-
viewing 26 men with TLE and comparing their en-
docrine status with age-matched controls. They found
23% of the men with epilepsy reported erectile or ejac-
ulatory dysfunction, of which three-quarters had low
FT levels. In addition, 27% had never experienced
spontaneous morning erections. Over a quarter denied
any sexual drive, and most of these men also had low
FT levels. However, the relationship between testos-
terone and libido is unclear, as despite finding low
FT in over half their sample of male patients treated
with CBZ, only a third of them reported a low sex
drive. This may be because of denial or additional
factors such as oestradiol level (which was normal in
their study).
Herzog et al.145 found raised E2 levels in men
with partial seizures taking PHT. Herzog146 postu-
lated that hepatic microsomal enzyme inducing AEDs
could lower testosterone by inducing SHBG synthe-
sis and by inducing aromatase, which converts testos-
terone to oestradiol. Oestradiol constitutes only 1%
of male gonadal steroids but exerts approximately
half of the negative feedback on LH secretion. Sup-
pression of LH results in hypogonadotropic hypogo-
nadism, and chronically low testosterone to testicular
failure and hypergonadotropic hypogonadism. Oestra-
diol can also produce premature ageing of the hy-
pothalamic arcuate nucleus, which may also cause
hypogonadotropic hypogonadism, and premature de-
cline of testosterone levels. The decreased T/E2 ra-
tio stimulates additional SHBG synthesis. Eventually,
this could lead to a progressively increasing concen-
tration of SHBG with a progressively declining testos-
terone level. Since testosterone increases potency and
libido, and oestradiol lowers male sexual interest and
function, liver-enzyme inducing AEDs could result
in a clinically significant sexual dysfunction by the
above mechanisms. However, since sexual dysfunc-
tion can occur in patients taking non-liver-enzyme in-
ducing AEDs such as gabapentin31, 128, other factors
must also play a part.
Much less research has been published regard-
ing the endocrine effects of AEDs in women (Ta-
ble 4). Hepatic microsomal enzyme inducing anti-
convulsants increase SHBG (which binds oestrogen)
and transcortin (which binds progesterone). Testos-
terone is 53% bound to albumin and 45% bound to
SHBG, oestradiol is 68% bound to albumin and 30%
to SHBG, whereas progesterone is 53% bound to al-
bumin and 45% bound to transcortin. Therefore, in-
creases in the transport proteins produced by AEDs
will have a greater effect on testosterone and proges-
terone than oestradiol140. Isoja¨rvi139 found untreated
women with epilepsy had higher FT and LH than con-
trols. During CBZ treatment, serum E2, progesterone,
TT, FT, PRL and FSH concentrations did not change.
FAI decreased and SHBG increased after 2 months
of treatment and remained altered after 12 months of
CBZ. However, the women continued to have ovula-
tory cycles.
TT has been shown to be increased and the percent-
age of FT reduced in women with epilepsy147, how-
ever, others18, 24 have not found any difference in FT
levels between treated women and controls. Raised
SHBG has also been reported in women taking an-
ticonvulsants24, especially the liver-enzyme inducing
drugs, PB133, PHT133, 148 and CBZ18, 133, 139.
Duncan et al.24 assessed the sexual behaviour and
attitude of 159 treated and 36 untreated, women with
epilepsy, using the SES. They measured SHBG, TT
and FT in 88 of the treated patients. They found treated
women were more ‘moral’ and less open to psycho-
sexual stimulation, however the groups differed sig-
nificantly in their extent of further education which
influences the SES scores. Again, the use of the SES
may have confounded their results. The study divided
subjects into ‘treated’ and ‘untreated’, thus the authors
were not able to comment on the effect of individual
AEDs on sexual function or endocrine status.
Studies disputing the role of AEDs in sexual
dysfunction
The hyposexuality noted in two-thirds of Gastaut and
Collomb’s10 patients occurred in patients who were
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Table 4: Hormone changes reported in women with epilepsy.
Untreated PB/Prim PHT CBZ VPA POLY
SHBG ↔ 47,139 ↑ 133,166 ↑ 133,148 ↑ 18,47,139,166 ↔ 166 ↑ 47,139
TT ↔ 47,139 ↔ 133 ↔ 133 ↔ 18,47,133,139 ↑ 47,139,166 ↔ 47,139
FT ↑ 47,139 — — ↔ 18,47,139 ↑ 47,139 ↔ 47,139
FAI ↔ 47,139 — — ↓ 47,139 ↑ 166 —
DHAS ↔ 47,139 ↓ 166 — ↓ 18,47,139,166 ↑ 47,139 ↓ 47,139
↔ 166
E2 ↔ 47,139 ↔ 166 — ↔ 47,139 ↔ 47,139,166 ↔ 47,139
↓ (L)18
P ↔ 47,139 ↔ (L) 166 — ↓ (EF)47,139 ↓ (L)166 —
↔ (L)166
FSH ↔ 47,139 ↔ 166 — ↔ 47,139,166 ↔ 166 ↑ 47,139
↓ 18
LH ↑ 47,139I ↔ 166 — ↓ 47,139 ↑ (L)166 ↑ 47,139
↓ (F)18
SHBG: sex hormone binding globulin; TT: total testosterone; FT: free testosterone; FAI: free androgen index; E2: oestrogen; P: progesterone;
FSH: follicle stimulating hormone; LH: luteinizing hormone; ↑: increased; ↓: decreased;↔: as controls; EF: early follicular; F: follicular;
L: luteal phase.
Sources: Victor et al.148; Barragry et al.133; Isoja¨rvi et al.47, 139; Stoffel-Wagner et al.18; Murialdo et al.166
not on anticonvulsants and in some, control of seizures
with barbiturates or phenytoin led to a return of sexual
response.
Hierons and Saunders27 identified 15 patients with
temporal lobe disorders and erectile dysfunction but
normal libido. In three, (at least two of which had had
a head injury) impotence preceded the development of
epilepsy by 6–9 months, during which time no medi-
cation was taken.
Half the patients, who were observed to have ab-
normal LH values and responses to LHRH by Her-
zog et al.149 had not been receiving anticonvulsant
medication and the others had discontinued medica-
tion at least a month before the assessment. In a later
study, Herzog and co-workers60 found sexual dysfunc-
tion and low FT in half their sample of men with TLE.
They commented that in some patients these abnor-
malities could not be accounted for by anticonvulsant
medication. Taneja et al.130 found decreased TT and
increased LH and FSH along with lower volume of
seminal fluid, reduced spermatozoa concentration and
count in both untreated men with epilepsy and those
taking PHT.
Bergen et al.16 found no correlation between sex-
ual dysfunction in women and the number or duration
of use of AEDs. They also found no difference be-
tween patients taking liver-enzyme inducing anticon-
vulsants and those taking valproate, similarly, other
studies12, 48 have also failed to show a relationship be-
tween AEDs and sexual dysfunction.
Furthermore, a recent study50 found a normalization
in the endocrine status of men following successful
epilepsy surgery, despite remaining on liver-enzyme
inducing medication (CBZ).
MENSTRUAL DISTURBANCES AND THE
ASSOCIATION WITH ANTICONVULSANTS
This remains a controversial issue but an area in which
much recent interest has been generated.
Valproate has been associated with menstrual distur-
bances in women with epilepsy since the early 1980s’
study by Margraf and Dreifuss150, which described
eight women who developed amenorrhoea shortly af-
ter starting VPA. Six also complained of hyperphagia
and weight gain. In seven, however, normal menstru-
ation resumed after 6–20 months without altering the
dose of VPA.
Recent work has focused on the polycystic ovarian
syndrome (PCOS). Polycystic ovaries (PCO) are di-
agnosed when there are 10 or more cysts, 2–8 mm
in diameter, arranged around an echodense stroma151.
The polycystic ovarian syndrome is diagnosed when
PCO are associated with hyperandrogenism (mani-
fested clinically as hirsutism, acne and male pattern
baldness along with raised serum androgens). High
serum levels of LH along with low FSH are typi-
cally documented152. The prevalence of these condi-
tions varies between studies, with ranges of 5–33%
being reported153–156, both being more common in
obese subjects. The aetiology of PCO is unknown but
it may have a genetic, possibly autosomal dominant
inheritance. Women with polycystic ovaries may be
asymptomatic, but after a gain in weight may develop
hirsutism and menstrual cycle disturbance157. Obesity
and PCO appear to have a separate but synergistic
role in the production of insulin resistance152. More-
over, the onset of obesity just before or during pu-
berty may be a factor in the subsequent development
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of PCOS158. Insulin resistance results in hyperinsuli-
naemia. The high levels of insulin act on the liver in-
hibiting the production of SHBG, thus increasing free
testosterone, and on the ovary, stimulating excess ovar-
ian androgen production157. The combined effect may
result in anovulation and the altered ovarian morphol-
ogy typical of PCO158, 159.
There has been a recent surge of research in this
area, much of which has been conducted by Isoja¨rvi et
al. in Finland. In 1993, Isoja¨rvi et al.47 assessed 238
female outpatients with epilepsy. Menstrual distur-
bances were found in 20% compared with 16% of
women without epilepsy. The frequency of menstrual
disturbances was not related to seizure type, occur-
ring in 21% of women with PGE, 18% with par-
tial and 21% secondarily generalized seizures. Almost
half the women receiving VPA monotherapy had men-
strual disturbances, compared with a fifth taking CBZ
monotherapy and a quarter receiving a combination
of the two AEDs. No women with untreated epilepsy
reported menstrual disturbances. Sixty-eight percent
of the women taking VPA alone or in combination
with CBZ had polycystic ovaries or elevated serum
testosterone, however this figure rose to 80% if the
VPA was started before the age of 20. TT, FT and
DHAS were higher in women taking VPA monother-
apy than in controls. Women taking CBZ alone or in
combination with VPA had elevated SHBG levels. In
a later study, Isoja¨arvi et al.160 further evaluated 65 of
these women with menstrual disturbances, of which 22
received VPA and 43, CBZ monotherapy. PCO, hy-
perandrogenism, or both, were found in 64% of the
women on VPA monotherapy, 21% of those on CBZ
and 19% of controls. Obesity was noted in 59% on
VPA, 28% on CBZ and 12% of controls. An indis-
putable weight gain, (average 21 kg, range 8–49 kg)
was found in half the VPA-treated group, 82% of
patients who started VPA before the age of 20 but only
18% of the women starting VPA after the age of 20,
and almost three-quarters of the VPA-treated patients
with PCO/hyperandrogenism. The authors also found
that women on long-term VPA, especially those who
were obese, were hyperinsulinaemic. The same au-
thors substituted lamotrigine (LTG) for VPA in 12 of
the women with PCO or hyperandrogenism and this
resulted in a reduction in body mass index (BMI) and
reversal of hyperinsulinaemia, accompanied by nor-
malization of elevated testosterone levels. The total
number of polycystic ovaries decreased from 20 to
11 after 1 year of LTG treatment and the number of
women with bilateral disease decreased from nine to
four161. The same group162 investigated the effect of
VPA on endocrine function in 41 adolescent girls aged
between 8 and 18. Twenty-four suffered PGE, 10, par-
tial and 13, secondarily generalized seizures. Hyperan-
drogenism was found in 38% of the pre-pubertal, 36%
of the pubertal and 57% of the post-pubertal girls. In
addition, the post-pubertal girls taking VPA were more
obese than controls.
The above studies could be criticized for using ul-
trasound to diagnose polycystic ovaries, which may
be asymptomatic, and for having small numbers of
patients in each monotherapy group. In addition, the
cases of PCO were combined with those with hyper-
androgenism in isolation, for the purposes of analysis,
thus it is not possible to determine the actual number
of subjects with PCOS. However, case reports from
other centres (Damm et al.163 in Germany and Sharma
and Jacobs164 in the UK) have documented the PCO
syndrome in association with VPA.
However, menstrual disturbances have not only been
reported in women taking VPA. Herzog et al.45 found
no significant relationship between the occurrence of
menstrual disorders and AEDs. Bilo et al.46 docu-
mented menstrual irregularities in women with PGE.
Most of the women were taking AEDs (PB, VPA or
a combination of the two). No clear relationship with
medication was found and three women had devel-
oped the menstrual problems before AED treatment
was started. Cummings et al.49 found anovulatory cy-
cles to be more common in patients with TLE, who
were mainly treated with polytherapy, especially with
CBZ. Women with PGE, who were mainly treated
with VPA, had normal ovulatory function. Again, the
number of patients in each group was small. Muri-
aldo et al.165 assessed 101 women with epilepsy in
Italy and found menstrual irregularities in 22%, which
were independent from epilepsy type and origin of
focal discharges. Although PCO were diagnosed in
17% (using transabdominal suprapubic ultrasound),
and appeared to be associated with VPA treatment,
this rate is similar to that observed in normal popu-
lation studies. They did however find higher andro-
gen levels, a higher luteal LH/FSH ratio and a lower
luteal progesterone surge (suggesting an anovulatory
cycle) in VPA treated patients compared with con-
trols165, 166. Another recent study167 has not shown
a difference between the incidence of PCOS (defined
as hyperandrogenism combined with oligomenorrhoea
or amenorrhoea) between untreated PWE and those
medicated with VPA or CBZ. Similarly, Betts and
Yarrow168 found, using magnetic resonance imaging,
similar rates of PCO in women medicated with either
VPA or LTG. However, more women taking VPA had
hyperandrogenism suggesting that PCO may be a di-
rect effect of epilepsy per se, but the use of VPA in
these patients may result in the development of PCOS.
Although as yet the available information on the de-
velopment of PCOS in women with epilepsy is limited
and conflicting, it is an important area. Menstrual dis-
turbances do occur, and moreover fertility is reduced
in these women. The fact that VPA is associated with
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weight gain is not disputed and the relationship be-
tween weight gain around the time of puberty and the
subsequent development of PCOS is of concern be-
cause VPA is commonly used to treat absence seizures
in pre-pubertal girls. Further research is needed in this
area and large multicentre studies are currently being
performed169.
PSYCHIATRIC DISORDERS
Psychiatric disorders, both neurotic and psychotic, are
often associated with hyposexuality. One of the cardi-
nal features of clinical depression or anxiety states is
reduced libido, and erectile dysfunction is common in
patients with alcohol or drug dependence170, 171.
Several studies have found a high prevalence of psy-
chiatric morbidity in patients with epilepsy, especially
involving the temporal lobes. Pond and Bidwell172
documented mental problems in 29% of people with
epilepsy, rising to 50% in those with TLE. Edeh and
Toone173 found similar results in a community survey
(48% were ‘psychiatric cases’ and patients with TLE
had more anxiety and depression). Mendez et al.174
found 55% of outpatients with epilepsy reported de-
pression.
Medication used to treat psychiatric disorders, in-
cluding the older neuroleptics and antidepressants,
may also impair sexual function in both men and
women175, 176.
Many studies have either omitted patients with psy-
chiatric disturbance, or have not commented on or
assessed their mental health24, 25. However, recently,
Morrell and Guldner48 did not find any correlation
between sexual disorder and depression in a group
of PWE.
PSYCHOSOCIAL FACTORS
Thompson and Oxley177 examined the psychosocial
effects in 92 patients with poorly controlled epilepsy,
and found 68% had no personal friends, 34% never
formed true friendships, 57% had never had a steady
relationship and only 8% were married. Chaplin et
al.178 found that people with epilepsy identified sex-
ual relationships as an area of concern, along with lack
of confidence, increased isolation, lack of energy and
adverse reactions in their social life and leisure pur-
suits; all of which could contribute towards the devel-
opment of hyposexuality. Acceptance of the diagnosis
and of acquiring the label ‘epileptic’, have also been
shown to be areas of concern178. However, the reac-
tion of the partner may also be relevant. Partners of
people with epilepsy may become over-protective re-
sulting in their spouse losing their role as a ‘sexual
adult’ for that of an ‘invalid’ or ‘dependent’. Studies
of couples with a diabetic spouse found that only 15%
of couples with good disease acceptance, reported sex-
ual dysfunction, compared with 57% of those with
moderate or poor disease acceptance34. Hermann and
Wyler179 determined the locus of control for patients
with epilepsy. Persons who perceive events in their
lives as not being attributable to their own efforts but
rather to the effects of fate have an external locus
of control, whereas those who perceive events as be-
ing under their own influence have an internal lo-
cus of control. They found that depression was sig-
nificantly correlated with an external locus of control
pre- but not post-operatively. Locus of control may
well prove to be a major causal factor in the devel-
opment of sexual dysfunction in epilepsy. The lack of
significant difference in reported sexual dysfunction
between operated and non-operated patients described
by Christianson et al.54 may be explained by the sim-
ilarities in overall life satisfaction in the two groups.
A control group had both higher life satisfaction and
sexual drive.
Most workers have found that PWE tend to marry
less often than normal controls. Dansky et al.21 eval-
uated the marriage rate of Canadians with epilepsy,
three-quarters of which had developed habitual
seizures by the age of 20. They found that 61% of the
females and 38% of the males were or had been mar-
ried, which is 83% and 59% of the expected rate, re-
spectively. Patients (particularly males) with an early
onset of epilepsy were less likely to marry and 39%
of all patients who married did so prior to the onset of
their epilepsy. This confirms the earlier work of Tay-
lor3 who found that only 34% of his sample was mar-
ried. Marriage rates may be seen as a measure of desire
to enter into relationships in which sexual activity is
likely to occur. Monetary difficulties secondary to un-
employment, transport difficulties and low self-esteem
may also be factors involved in PWE not entering re-
lationships. These factors are likely to influence men
more than women. Development of sexual dysfunc-
tion would confirm negative thoughts about self-worth
and ability to participate in social relationships. Sex-
ual arousal may be negatively re-enforced in patients
with peri-ictal sexual sensations or seizures occurring
during sexual activity.
TREATMENT OF SEXUAL DYSFUNCTION IN
PWE
Sexual dysfunction, whether of physiological or psy-
chological cause may be treatable34. However, there
have been very few studies conduced in PWE, and
all have been performed in men. Daniels et al.180
found improvement in sexual functioning (increased
334 M. V. Lambert
frequency of morning erections, longer-lasting pe-
nile tumescence and greater frequency of reaching or-
gasm) accompanied by improved seizure control in a
placebo-controlled pilot study of intramuscular testos-
terone. During treatment, LH and FSH levels fell, sug-
gesting that the feedback loop on the anterior pitu-
itary was functioning normally. Herzog146 also found
a moderate improvement in hyposexuality with testos-
terone, but he concluded that the addition of testos-
terone alone was not sufficient to produce a marked
improvement in sexual functioning because the aro-
matase induced by the AEDs converted the additional
testosterone into oestradiol. He produced improve-
ment in both sexuality and seizure frequency in a man
treated with CBZ by adding the aromatase inhibitor—
testolactone, along with testosterone. However, these
two studies involved small numbers of patients and
further research is needed in this area.
Sildenafil (Viagra) has been shown to improve both
the quality and frequency of erections, regardless of
the aetiology (organic or psychogenic), whilst not af-
fecting libido181. Although the medication has not
been studied in patients with epilepsy, there were no
reports of convulsions during the clinical trials. Post-
marketing surveillance has detected some reports of
convulsions, however in most cases there were other
contributing factors such as concurrent use of pro-
convulsant medication. Sildenafil is metabolized by
the cytochrome P450 3A4 enzyme system, therefore
concomitant use of liver-enzyme inducing AEDs may
speed up its removal (Pfizer, 1999, Personal commu-
nication).
Treatment of sexual dysfunction in women with
epilepsy is a much-neglected area, and more studies
need to be performed.
DISCUSSION
Many of the above studies are flawed, by being ret-
rospective, not using a control group, using non-
representative hospital samples and not clearly docu-
menting the seizure type. However, most concur that
hyposexuality and endocrine disorders are associated
with epilepsy. However, the aetiology remains uncer-
tain, but is likely to be multifactorial in origin in-
volving neurological, endocrine, iatrogenic, psychi-
atric, cognitive and psychosocial factors. Most stud-
ies revealed endocrine abnormalities in both men and
women with epilepsy, especially when treated with
liver-enzyme inducing anticonvulsants. However, in
the majority of these studies, concurrent assessment of
desire and functioning has not been performed. Thus
the effect of the hormonal abnormalities remains un-
certain. The exceptions being the studies by Toone’s
group55, 134 in which low drive was correlated with
reduced FT. Anticonvulsant medication cannot be the
sole cause of the sexual dysfunction, as in some stud-
ies the hyposexuality and/or endocrine changes pre-
dated starting the AED. Furthermore, in some cases,
relief of seizures with surgery resulted in an im-
provement in sexual functioning despite remaining on
medication.
The incidence of sexual dysfunction varies from
study to study, however in patients with active
epilepsy, rates of hyposexuality appear to be high,
even in drug-free patients. It may be that a combina-
tion of factors is needed in order for the full spectrum
of sexual dysfunction to develop.
It is a striking finding in many studies3, 29, 30 that
patients with epilepsy do not complain of and appear
unconcerned about their hyposexuality, especially if
their seizures began pre-pubertally. Bergen et al.16
noted that out of the 17 women in their sample with
hyposexuality, only seven had discussed this with a
physician. They also commented that only 13% of
their entire sample had ever been asked about their
sexual function. Reasons for this could include:
(1) If the seizures and sexual disorder began pre-
pubertally, i.e. before the onset of ‘normal’ sex-
ual desire and function, the patient may not be
aware of the dysfunction.
(2) The patient and/or member of the medical pro-
fession may not be aware of the association
between epilepsy and sexual dysfunction and
therefore may not think to explore the topic in
the epilepsy clinic.
(3) Sexuality is a subject that may people (both
patients and healthcare workers) often find dif-
ficult to discuss.
A questionnaire survey of 400 American physicians
revealed that only a fifth of responding doctors be-
lieved that patients with TLE had a lower libido com-
pared with people without epilepsy and 35% believed
that the patients with TLE had a higher libido. The
physicians believed that performance anxiety and low
self-esteem were the most likely causes of sexual dys-
function in male and female patients with epilepsy, re-
spectively182.
However, when patients are asked about sexual
function, most appear eager to discuss it and undergo
any necessary evaluations and are often relieved to dis-
cover that the problem is not unique to them.
Sexual function is an important marker of well-
being and since patients with epilepsy may not sponta-
neously complain of dysfunction, physicians and other
health care workers should always discuss it when in-
terviewing patients. Bignell183 has stressed the impor-
tance of communication skills in improving the ‘sex-
ual health of the nation’.
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The effect of epilepsy treatment on sexuality is an
important area for research, both to discover more
about the aetiology of sexual dysfunction and also to
help counsel patients before starting new treatments.
Fenwick184 suggested that determination of sexual
functioning should be included in the pre-surgical in-
vestigations. This should be combined with a full
neuropsychiatric evaluation, including assessment of
mental state along with quality of life and locus of
control measures. Such studies would help to evalu-
ate the effects on sexual functioning of the different
neurosurgical treatments for epilepsy: callosotomy,
hemispherectomy, temporal lobectomy, amygdalo-
hippocampectomy and vagus nerve stimulation.
The hormonal actions of the AEDs also need fur-
ther documentation, evaluating the effects of single
drugs on the sexual function and endocrine status of
both men and women with epilepsy, taking into ac-
count neuropsychiatric factors such as depression and
anxiety and controlling for age and circadian rhythms.
Since most of the studies on sexuality in epilepsy were
performed, many new anticonvulsants have become
available in the UK, including vigabatrin, lamotrig-
ine, gabapentin, topiramate and tiagabine. These drugs
do not appear to induce the hepatic-microsomal sys-
tem185, therefore evaluation of the effect of these on
sexual desire and function, combined with neuroen-
docrine studies, would be an exciting area of future
research. In addition, many of the recognized AEDs,
both liver-enzyme inducing (CBZ) and not (VPA,
LTG, GBP), are being used more frequently in patients
with disorders such as manic depressive psychoses and
chronic pain, but without a history of epilepsy. Eval-
uation of the sexual function and endocrine status of
these patients will help to separate the effects of the
drugs from the underlying seizure disorder in PWE.
SUMMARY
Seizures, hormones and sexual function have a com-
plex relationship and much is still not understood
about the interaction between them. As yet, no defini-
tive study has been performed to determine the inci-
dence of hyposexuality in PWE. There is no doubt
that hormonal changes occur which may in part be
related to the use of liver-enzyme inducing medica-
tion. However, it is not known whether the reported re-
duction in free testosterone results in hyposexuality. A
large, prospective (probably multicentre) study needs
to be performed to attempt to determine the effects of
epilepsy per se and the individual treatments on sex-
ual functioning and endocrine status, taking into ac-
count the psychosocial factors. The lack of available
questionnaires covering both sexual desire and func-
tion that can be administered to all PWE hinders re-
search in this area. In addition, studies of treatment of
sexual dysfunction in PWE are lacking, in particular,
no major studies have been performed observing the
effects of testosterone replacement therapy.
Much less research has been performed in women,
possibly because of the difficulties in taking blood for
endocrine studies at the appropriate time in the men-
strual cycle; however more research is needed to ex-
plore issues such as catamenial epilepsy and the effect
of the menopause and hormone replacement therapy.
Much recent interest has been shown in the fertility
issues in women, especially in relation to the PCOS.
However, hyposexuality and impotence in men is po-
tentially a major source of infertility and this area de-
serves more attention. The cause of the sexual dys-
function is likely to be multifactorial and it may be that
some factors (such as psychosocial and psychiatric
disorders) may result in a reduction in libido and oth-
ers (such as seizures and medication) may be responsi-
ble for the endocrine changes and the sexual dysfunc-
tion. However, there remains the possibility that the
liver-enzyme inducing AEDs may play a major role
in the development of these problems, and as there
are now many effective alternatives, research studies
should focus on this area.
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